# Neurocognitive Outcome of Bilateral or Unilateral Hippocampal Avoidance WBRT With Memantine for Brain Metastases

> **NCT04801342** · PHASE2 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 72 (estimated)

## Conditions studied

- Metastatic Malignant Neoplasm to Brain

## Interventions

- **RADIATION:** Conformal Whole Brain Radiotherapy with Unilateral Hippocampal Avoidance
- **RADIATION:** Conformal Whole Brain Radiotherapy with Bilateral Hippocampal Avoidance
- **DRUG:** Memantine Hydrochloride

## Key facts

- **NCT ID:** NCT04801342
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2024-01-01
- **Final completion:** 2025-02-28
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2021-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04801342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04801342, "Neurocognitive Outcome of Bilateral or Unilateral Hippocampal Avoidance WBRT With Memantine for Brain Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04801342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*